Exato Technologies Ltd
544626Exato Technologies Ltd is strength at full price. The numbers are improving — and a P/E at the 100th percentile of its own range says the market knows.
The sharpest disagreement: profits are rising, but only 3% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a confirmed uptrend (39 weeks in) while the P/E sits at the 100th percentile of its own 1-year range. Underneath, the last four quarters read improving — profit +104.3% year on year, and 3% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Exato Technologies Ltd trades at ₹754, in a confirmed uptrend and 39 weeks into that stage. That is +63.7% against its own 200-day average. It sits at 100% of a 52-week range of ₹354 to ₹754. On relative strength it has no relative-strength read yet.
Today the stock is in a confirmed uptrend — week 39 of stage 2, confirmed. At ₹754 it trades +63.7% versus its 200-day average and sits at 100% of its 52-week range (₹354–₹754).
Against the market, two honest reads. Cumulative: over the last 4 months the stock moved +113% while the NIFTY 500 moved +1% — ahead of the index over the full window. Recent form: no trailing-13-week read yet — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Exato Technologies Ltd trades at 40.0× P/E, about the priciest it has ever traded. Its long-run median P/E is 0.1×, measured across 0.8 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 40.0× is about the priciest it has ever traded, against a long-run median of 0.1× measured over 0.8 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Exato Technologies Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +35.5% | +32.0% | — | — |
| Profit | +60.0% | +47.4% | — | — |
| EPS | −99.8% | −84.2% | — | — |
4-Factor Sector Score
57.8/100 — rank 57 of 64 in IT - Software · 38% evidence confidence · provisional, ranked below fully-evidenced peers
Exato Technologies Ltd scores 57.8 out of 100 against the 64 companies it is compared with in IT - Software, ranking 57. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 21 + 17.5 + 9.3 + 10 = 57.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Exato Technologies Ltd reported ₹43.7 Cr of revenue in the Jun 26 quarter, +50.2% year on year. That is the 3rd straight quarter of year-on-year growth. Over 3 years it has compounded at 32.0% a year. The last full year, FY26, came in at ₹168 Cr. The last four reported quarters add to ₹183 Cr.
FY26 revenue came in at ₹168 Cr (+35.5% on the year), capping 3 years at 32.0% compound. The latest quarter (Jun 26) printed ₹43.7 Cr, +50.2% year on year — the 3rd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +25.5% growth against the decade's 32.0% — the current year is running slower than its own long-run rate.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Exato Technologies Ltd's operating margin is 18.0% in the Jun 26 quarter, +3.4 percentage points against the same quarter a year ago. Across 4 fiscal years the operating margin has ranged 7.0% to 14.0%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 18.0%, +3.4 pp against the same quarter a year ago. Across 4 fiscal years the operating margin has ranged 7.0%–14.0%.
Why the margin moved: operating margin went +3.4 pp year on year while gross margin went −1.7 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Exato Technologies Ltd earned ₹5.6 Cr of net profit in the Jun 26 quarter, +104.3% year on year. Full-year FY26 profit was ₹16.0 Cr. The 3-year compound rate is 47.4%. That is 12.9% of the quarter's revenue. The same quarter a year earlier earned ₹2.8 Cr.
Jun 26 profit was ₹5.6 Cr, +104.3% year on year. On the full year, FY26 printed ₹16.0 Cr (+60.0%), and the 3-year compound rate is 47.4%.
Why profit moved: revenue contributed +50.2% and the margin +3.4 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +55.7% vs revenue +25.5%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 3% of Exato Technologies Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹2.0 Cr of operating cash against ₹16.0 Cr of profit. After ₹13.0 Cr of capital spending, ₹−11.0 Cr was left as free cash.
FY26: operating cash of ₹2.0 Cr against reported profit of ₹16.0 Cr, leaving free cash of ₹−11.0 Cr after ₹13.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 3% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 3%: the cash cycle stretched 65 days between FY23 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 65 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Exato Technologies Ltd's cash conversion cycle runs 80 days in FY26, up from 15 days in FY23. Capital spending ran ₹32.0 Cr over the last 3 years. At FY26 sales of ₹168 Cr each day of that cycle holds about ₹0.5 Cr, so roughly ₹37.0 Cr sits inside the business at any moment.
FY26: debtors at 93 days, inventory at 11 days — roughly 0.4 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 80 days, looser than FY23's 15.
The full loop: cash goes out to suppliers and production on day 0; stock waits 11 days to sell; customers pay about 93 days after that; and suppliers themselves are paid at 24 days — netting out to the 80-day cycle.
In money terms: at FY26 sales of ₹168 Cr, each day of the cycle holds about ₹0.5 Cr — so the 80-day loop keeps roughly ₹37.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹32.0 Cr over the last 3 fiscal years against ₹2.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Exato Technologies Ltd earns a ROCE of 27% in FY26. That is up from a trough of 25% in FY24. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 9.5% net margin on 1.37× asset turns.
FY26 ROCE is 27%, recovered from a FY24 trough of 25% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 9.5% net margin × 1.37× asset turns × 1.40× balance-sheet leverage ≈ 18.2% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Exato Technologies Ltd carries ₹21.0 Cr of borrowings against ₹88.0 Cr of equity in FY26, a debt-to-equity of 0.24. Operating profit covers the interest bill 12×. Over 3 years borrowings went from ₹6.0 Cr to ₹21.0 Cr. Capital spending ran ₹32.0 Cr across the last 3 of those years.
FY26: borrowings of ₹21.0 Cr against equity of ₹88.0 Cr — a debt-to-equity of 0.24. Operating profit covers the interest bill 12×. Over 3 years borrowings went from ₹6.0 Cr to ₹21.0 Cr while capital spending ran ₹32.0 Cr in just the last 3 — part of the build-out is riding on borrowed money.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Exato Technologies Ltd moved a full percentage point over the last two years — the register is quiet. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — .
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Exato Technologies Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Coforge LtdCOFORGE | 76.3/100Favorable setup100% evidence | LEADER | 30.0/35 Revenue 35.7% · PAT 66.5% · OPM change 3 pp 100% evidence | 15.6/25 ROCE 23.5% · OPM 19% 100% evidence | 12.3/20 P/E 42.7× · PEG 0.57 100% evidence | 18.4/20 RS sector 13.3% · RS bench 20.1% · 1Y 11.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 30 + 15.6 + 12.3 + 18.4 = 76.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Silver Touch Technologies LtdSILVERTUC | 70.0/100Favorable setup93% evidence | FADING | 30.2/35 Revenue 21.1% · PAT 86.4% · OPM change 8 pp 100% evidence | 17.4/25 ROCE 29.8% · OPM 22% 100% evidence | 10.3/20 P/E 46.4× · PEG 1.11 65% evidence | 12.1/20 RS sector 6.1% · RS bench 14.1% · 1Y 120.3%9 of 12 weeks ahead 100% evidence |
| Exact sum: 30.2 + 17.4 + 10.3 + 12.1 = 70 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3Sahana Systems LtdSAHANA | 68.7/100Favorable setup70% evidence | TURNING | 21.5/35 Revenue 100% · PAT 100% · OPM change -3 pp 48% evidence | 19.9/25 ROCE 39.8% · OPM 29% 95% evidence | 13.4/20 P/E 14.1× · PEG — 50% evidence | 13.9/20 RS sector -5.2% · RS bench 15.9% · 1Y -24.3%3 of 12 weeks ahead 100% evidence |
| Exact sum: 21.5 + 19.9 + 13.4 + 13.9 = 68.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4ASM Technologies Ltd526433 | 68.2/100Favorable setup69% evidence | BREAKING OUT | 27.9/35 Revenue 67.8% · PAT 89.5% · OPM change 2 pp 95% evidence | 16.1/25 ROCE 27% · OPM 23% 76% evidence | 8.6/20 P/E 138× · PEG — 15% evidence | 15.6/20 RS sector 5.7% · RS bench 97.1% · 1Y 94%10 of 10 weeks ahead 70% evidence |
| Exact sum: 27.9 + 16.1 + 8.6 + 15.6 = 68.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5NINtec Systems LtdNINSYS | 65.0/100Favorable setup80% evidence | FADING | 20.0/35 Revenue 21.6% · PAT 18.8% · OPM change 4.2 pp 95% evidence | 21.9/25 ROCE 54% · OPM 25.9% 95% evidence | 9.3/20 P/E 39.3× · PEG — 15% evidence | 13.8/20 RS sector 29.6% · RS bench 37.6% · 1Y 57.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 20 + 21.9 + 9.3 + 13.8 = 65 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6String Metaverse Ltd534535 | 63.4/100Mixed-positive evidence82% evidence | BASING | 27.2/35 Revenue 100% · PAT 100% · OPM change 0 pp 95% evidence | 15.7/25 ROCE 41.6% · OPM 11% 76% evidence | 14.8/20 P/E 8.2× · PEG — 50% evidence | 5.7/20 RS sector -48% · RS bench -35.6% · 1Y -70.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 27.2 + 15.7 + 14.8 + 5.7 = 63.4 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -48% and the one-year return is -70.4%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 7Cigniti Technologies LtdCIGNITITEC | 63.3/100Mixed-positive evidence73% evidence | 23.4/35 Revenue 14% · PAT 96.1% · OPM change 2 pp 56% evidence | 16.2/25 ROCE 34.1% · OPM 18% 75% evidence | 16.2/20 P/E 11.4× · PEG 0.61 100% evidence | 7.5/20 RS sector -10.2% · RS bench -15% · 1Y -19.7%0 of 12 weeks ahead to 2026-05-17 70% evidence | |
| Exact sum: 23.4 + 16.2 + 16.2 + 7.5 = 63.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Tech Mahindra LtdTECHM | 63.2/100Mixed-positive evidence94% evidence | BREAKING OUT | 21.1/35 Revenue 10.9% · PAT 14.3% · OPM change 3 pp 100% evidence | 16.3/25 ROCE 23.1% · OPM 17% 100% evidence | 10.6/20 P/E 28.4× · PEG 0.76 100% evidence | 15.2/20 RS sector 14.8% · RS bench 4% · 1Y 4.3%8 of 11 weeks ahead 70% evidence |
| Exact sum: 21.1 + 16.3 + 10.6 + 15.2 = 63.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9TAC Infosec LtdTAC | 63.0/100Mixed-positive evidence66% evidence | TURNING | 25.6/35 Revenue 76.4% · PAT 59.4% · OPM change 1.6 pp 71% evidence | 20.9/25 ROCE 38.1% · OPM 48.2% 95% evidence | 9.5/20 P/E 35.7× · PEG — 15% evidence | 7.0/20 RS sector -13.2% · RS bench -15.4% · 1Y -14.4%4 of 10 weeks ahead 70% evidence |
| Exact sum: 25.6 + 20.9 + 9.5 + 7 = 63 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Sasken Technologies LtdSASKEN | 61.6/100Mixed-positive evidence100% evidence | FADING | 30.7/35 Revenue 67.8% · PAT 67.4% · OPM change 4 pp 100% evidence | 8.1/25 ROCE 9.9% · OPM 9% 100% evidence | 10.4/20 P/E 36.7× · PEG 0.68 100% evidence | 12.4/20 RS sector 9.5% · RS bench 16.6% · 1Y 25%8 of 12 weeks ahead 100% evidence |
| Exact sum: 30.7 + 8.1 + 10.4 + 12.4 = 61.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Softtech Engineers LtdSOFTTECH | 60.8/100Mixed-positive evidence80% evidence | TURNING | 25.2/35 Revenue 35.8% · PAT 100% · OPM change -0.1 pp 95% evidence | 12.1/25 ROCE 6.2% · OPM 27.2% 95% evidence | 8.7/20 P/E 124× · PEG — 15% evidence | 14.8/20 RS sector 19.9% · RS bench 27.6% · 1Y 13.7%6 of 12 weeks ahead 100% evidence |
| Exact sum: 25.2 + 12.1 + 8.7 + 14.8 = 60.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Datamatics Global Services LtdDATAMATICS | 60.7/100Mixed-positive evidence94% evidence | ASLEEP | 21.0/35 Revenue 13.1% · PAT 1.9% · OPM change 4 pp 100% evidence | 15.9/25 ROCE 20.4% · OPM 20% 100% evidence | 10.6/20 P/E 17.7× · PEG 0.69 100% evidence | 13.2/20 RS sector 9.6% · RS bench -3.3% · 1Y -21.3%5 of 10 weeks ahead 70% evidence |
| Exact sum: 21 + 15.9 + 10.6 + 13.2 = 60.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13IZMO LtdIZMO | 60.6/100Mixed-positive evidence81% evidence | FADING | 24.1/35 Revenue 24.7% · PAT 10.2% · OPM change 8 pp 95% evidence | 14.2/25 ROCE 12.6% · OPM 25% 95% evidence | 6.6/20 P/E 25.3× · PEG — 50% evidence | 15.7/20 RS sector 29% · RS bench 7.6% · 1Y 20.9%8 of 10 weeks ahead 70% evidence |
| Exact sum: 24.1 + 14.2 + 6.6 + 15.7 = 60.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Danlaw Technologies India Ltd532329 | 59.9/100Mixed-positive evidence67% evidence | TURNING | 21.8/35 Revenue 24.1% · PAT 34.5% · OPM change 0.8 pp 95% evidence | 15.5/25 ROCE 27.6% · OPM 13.4% 76% evidence | 10.2/20 P/E 32× · PEG — 50% evidence | 12.4/20 RS sector — · RS bench 93% · 1Y —4 of 4 weeks ahead 25% evidence |
| Exact sum: 21.8 + 15.5 + 10.2 + 12.4 = 59.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Expleo Solutions LtdEXPLEOSOL | 59.6/100Mixed-positive evidence81% evidence | TURNING | 20.9/35 Revenue 10.4% · PAT 39.4% · OPM change 4 pp 95% evidence | 15.8/25 ROCE 24.2% · OPM 15% 95% evidence | 13.7/20 P/E 9.4× · PEG — 50% evidence | 9.2/20 RS sector -13.3% · RS bench 1.4% · 1Y -12.8%2 of 10 weeks ahead 70% evidence |
| Exact sum: 20.9 + 15.8 + 13.7 + 9.2 = 59.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Hypersoft Technologies Ltd539724 | 59.6/100Mixed-positive evidence67% evidence | FADING | 25.5/35 Revenue 100% · PAT 100% · OPM change 2.9 pp 71% evidence | 11.9/25 ROCE 20.6% · OPM 14% 76% evidence | 8.6/20 P/E 386× · PEG — 15% evidence | 13.6/20 RS sector 40.8% · RS bench 50.5% · 1Y 116.6%10 of 12 weeks ahead 100% evidence |
| Exact sum: 25.5 + 11.9 + 8.6 + 13.6 = 59.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17InfoBeans Technologies LtdINFOBEAN | 58.9/100Mixed-positive evidence87% evidence | ASLEEP | 26.5/35 Revenue 35.5% · PAT 60.4% · OPM change 0 pp 95% evidence | 16.9/25 ROCE 29.2% · OPM 21% 95% evidence | 9.7/20 P/E 17.6× · PEG — 50% evidence | 5.8/20 RS sector -12.9% · RS bench -6.5% · 1Y 10.4%3 of 12 weeks ahead 100% evidence |
| Exact sum: 26.5 + 16.9 + 9.7 + 5.8 = 58.9 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -12.9% and the one-year return is 10.4%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 18R Systems International LtdRSYSTEMS | 57.5/100Mixed-positive evidence100% evidence | BASING | 18.9/35 Revenue 24.1% · PAT -1% · OPM change 3 pp 100% evidence | 16.5/25 ROCE 19.5% · OPM 18% 100% evidence | 17.7/20 P/E 13.5× · PEG 0.26 100% evidence | 4.4/20 RS sector -28.2% · RS bench -23.7% · 1Y -46.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 16.5 + 17.7 + 4.4 = 57.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Ksolves India LtdKSOLVES | 57.3/100Mixed-positive evidence87% evidence | ASLEEP | 17.8/35 Revenue 16% · PAT 16.7% · OPM change 3.9 pp 95% evidence | 20.7/25 ROCE 131% · OPM 30.3% 95% evidence | 13.8/20 P/E 16.5× · PEG — 50% evidence | 5.0/20 RS sector -16.6% · RS bench -10.9% · 1Y -19.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.8 + 20.7 + 13.8 + 5 = 57.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20BLS E-Services LtdBLSE | 56.8/100Mixed-positive evidence75% evidence | LEADER | 18.1/35 Revenue 71.2% · PAT 9.4% · OPM change 0 pp 95% evidence | 10.3/25 ROCE 16.4% · OPM 7% 76% evidence | 9.0/20 P/E 48.9× · PEG — 15% evidence | 19.4/20 RS sector 41.8% · RS bench 50.4% · 1Y 75.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 10.3 + 9 + 19.4 = 56.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Subex LtdSUBEXLTD | 56.5/100Mixed-positive evidence65% evidence | BREAKING OUT | 24.4/35 Revenue 2.8% · PAT 100% · OPM change 13 pp 95% evidence | 10.3/25 ROCE 12.8% · OPM 19% 95% evidence | 9.4/20 P/E 36.2× · PEG — 15% evidence | 12.4/20 RS sector — · RS bench 80.4% · 1Y —9 of 9 weeks ahead 25% evidence |
| Exact sum: 24.4 + 10.3 + 9.4 + 12.4 = 56.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Saksoft LtdSAKSOFT | 55.7/100Mixed-positive evidence100% evidence | BREAKING OUT | 17.9/35 Revenue 8.2% · PAT 13% · OPM change 0 pp 100% evidence | 15.6/25 ROCE 25.5% · OPM 18% 100% evidence | 13.5/20 P/E 14.5× · PEG 0.6 100% evidence | 8.7/20 RS sector -16% · RS bench -10.8% · 1Y -30.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 15.6 + 13.5 + 8.7 = 55.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Infosys LtdINFY | 55.1/100Mixed-positive evidence82% evidence | ASLEEP | 18.1/35 Revenue 11.2% · PAT 11.1% · OPM change 0 pp 95% evidence | 20.1/25 ROCE 40% · OPM 24% 76% evidence | 14.0/20 P/E 13.5× · PEG — 50% evidence | 2.9/20 RS sector -26.2% · RS bench -21.2% · 1Y -28.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 20.1 + 14 + 2.9 = 55.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24LTM LtdLTM | 54.4/100Mixed-positive evidence100% evidence | BREAKING OUT | 17.1/35 Revenue 13.9% · PAT 10% · OPM change 1 pp 100% evidence | 17.9/25 ROCE 29.6% · OPM 18% 100% evidence | 10.7/20 P/E 22.6× · PEG 1.18 100% evidence | 8.7/20 RS sector -17.1% · RS bench -11.7% · 1Y -17.7%5 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 17.9 + 10.7 + 8.7 = 54.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25AvenuesAI LtdCCAVENUE | 53.6/100Mixed-positive evidence93% evidence | BREAKING OUT | 20.9/35 Revenue 100% · PAT 43.8% · OPM change -2.3 pp 100% evidence | 5.0/25 ROCE 7.7% · OPM 3.7% 100% evidence | 14.8/20 P/E 19.2× · PEG 0.37 65% evidence | 12.9/20 RS sector -4.7% · RS bench 1.7% · 1Y 0.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 20.9 + 5 + 14.8 + 12.9 = 53.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Xchanging Solutions LtdXCHANGING | 53.6/100Mixed-positive evidence81% evidence | TURNING | 18.6/35 Revenue 8.4% · PAT 13.2% · OPM change 1 pp 95% evidence | 15.5/25 ROCE 18% · OPM 34% 95% evidence | 13.6/20 P/E 11.4× · PEG — 50% evidence | 5.9/20 RS sector -24.4% · RS bench -11.2% · 1Y -30.2%1 of 10 weeks ahead 70% evidence |
| Exact sum: 18.6 + 15.5 + 13.6 + 5.9 = 53.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Blue Cloud Softech Solutions LtdBLUECLOUDS | 53.0/100Mixed-positive evidence74% evidence | 22.0/35 Revenue 41.1% · PAT 36.2% · OPM change 10 pp 95% evidence | 12.4/25 ROCE 14.2% · OPM 20% 95% evidence | 9.6/20 P/E 27.6× · PEG — 15% evidence | 9.0/20 RS sector -3.8% · RS bench -8.7% · 1Y -33.2%1 of 12 weeks ahead 70% evidence | |
| Exact sum: 22 + 12.4 + 9.6 + 9 = 53 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28TechNVision Ventures LtdTECHNVISN | 52.9/100Mixed-positive evidence74% evidence | ASLEEP | 25.9/35 Revenue 23.4% · PAT 100% · OPM change 2.9 pp 95% evidence | 5.5/25 ROCE 12.9% · OPM 5.2% 95% evidence | 8.5/20 P/E 1002× · PEG — 15% evidence | 13.0/20 RS sector 32.1% · RS bench -14% · 1Y -20.6%0 of 9 weeks ahead 70% evidence |
| Exact sum: 25.9 + 5.5 + 8.5 + 13 = 52.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Seshaasai Technologies LtdSTYL | 52.3/100Mixed-positive evidence73% evidence | BREAKING OUT | 12.6/35 Revenue 6.7% · PAT 20.6% · OPM change 0 pp 100% evidence | 17.1/25 ROCE 27.7% · OPM 23% 100% evidence | 12.6/20 P/E 23.7× · PEG 0.81 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y -9.1%10 of 10 weeks ahead 0% evidence |
| Exact sum: 12.6 + 17.1 + 12.6 + 10 = 52.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30Tanla Platforms LtdTANLA | 52.2/100Mixed-positive evidence94% evidence | ASLEEP | 14.4/35 Revenue 13.2% · PAT 9.9% · OPM change 0 pp 100% evidence | 16.5/25 ROCE 26.3% · OPM 16% 100% evidence | 13.1/20 P/E 12.5× · PEG 1.21 100% evidence | 8.2/20 RS sector -12% · RS bench -5.7% · 1Y -23.7%6 of 10 weeks ahead 70% evidence |
| Exact sum: 14.4 + 16.5 + 13.1 + 8.2 = 52.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 31Tata Consultancy Services LtdTCS | 50.6/100Mixed-positive evidence100% evidence | TURNING | 10.0/35 Revenue 7.7% · PAT 1.1% · OPM change -1 pp 100% evidence | 22.5/25 ROCE 63% · OPM 26% 100% evidence | 11.9/20 P/E 14.8× · PEG 1.85 100% evidence | 6.2/20 RS sector -21.5% · RS bench -16.2% · 1Y -27.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 10 + 22.5 + 11.9 + 6.2 = 50.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 32Capillary Technologies India LtdCAPILLARY | 50.4/100Mixed-positive evidence63% evidence | ASLEEP | 27.4/35 Revenue 27.8% · PAT 135.8% · OPM change 5.8 pp 100% evidence | 4.1/25 ROCE 3.4% · OPM 15.7% 100% evidence | 8.9/20 P/E 71.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 10 weeks ahead 0% evidence |
| Exact sum: 27.4 + 4.1 + 8.9 + 10 = 50.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 33RNIT AI Solutions LtdAUTOPALIND | 50.4/100Thin evidence · provisional55% evidence | BREAKING OUT | 16.9/35 Revenue 56.7% · PAT 71.3% · OPM change -0.6 pp 95% evidence | 14.6/25 ROCE 20.2% · OPM 35.3% 76% evidence | 8.9/20 P/E 68× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —5 of 12 weeks ahead 0% evidence |
| Exact sum: 16.9 + 14.6 + 8.9 + 10 = 50.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 34Birlasoft LtdBSOFT | 50.3/100Mixed-positive evidence100% evidence | ASLEEP | 19.7/35 Revenue 1.4% · PAT 21.1% · OPM change 4 pp 100% evidence | 13.0/25 ROCE 21.2% · OPM 16% 100% evidence | 14.6/20 P/E 13.2× · PEG 0.62 100% evidence | 3.0/20 RS sector -26% · RS bench -20.6% · 1Y -25%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 13 + 14.6 + 3 = 50.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 35Mphasis LtdMPHASIS | 49.0/100Mixed-negative evidence94% evidence | FADING | 15.0/35 Revenue 13.7% · PAT 9.9% · OPM change -1 pp 100% evidence | 17.3/25 ROCE 22.1% · OPM 18% 100% evidence | 6.0/20 P/E 22.6× · PEG 2.19 100% evidence | 10.7/20 RS sector 0% · RS bench -7% · 1Y -18%3 of 10 weeks ahead 70% evidence |
| Exact sum: 15 + 17.3 + 6 + 10.7 = 49 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 36Hexaware Technologies LtdHEXT | 48.9/100Mixed-negative evidence94% evidence | FADING | 14.2/35 Revenue 13% · PAT 1.2% · OPM change 4 pp 100% evidence | 17.8/25 ROCE 30.1% · OPM 16% 100% evidence | 10.7/20 P/E 21.4× · PEG 0.81 100% evidence | 6.2/20 RS sector -21.4% · RS bench -14.7% · 1Y -31.1%6 of 10 weeks ahead 70% evidence |
| Exact sum: 14.2 + 17.8 + 10.7 + 6.2 = 48.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 37HCL Technologies LtdHCLTECH | 48.2/100Mixed-negative evidence82% evidence | BREAKING OUT | 12.2/35 Revenue 12.6% · PAT 2.6% · OPM change 0 pp 95% evidence | 19.0/25 ROCE 30.4% · OPM 20% 76% evidence | 9.0/20 P/E 18× · PEG — 50% evidence | 8.0/20 RS sector -18.3% · RS bench -12.7% · 1Y -15%7 of 12 weeks ahead 100% evidence |
| Exact sum: 12.2 + 19 + 9 + 8 = 48.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 38Mastek LtdMASTEK | 47.9/100Mixed-negative evidence82% evidence | FADING | 13.8/35 Revenue 6% · PAT 5% · OPM change 0 pp 95% evidence | 13.3/25 ROCE 17.7% · OPM 15% 76% evidence | 12.6/20 P/E 11.5× · PEG — 50% evidence | 8.2/20 RS sector -16.4% · RS bench -11.1% · 1Y -33.2%4 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 13.3 + 12.6 + 8.2 = 47.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 39Dynacons Systems & Solutions LtdDSSL | 47.2/100Mixed-negative evidence87% evidence | ASLEEP | 16.8/35 Revenue 10.5% · PAT 16.2% · OPM change 3 pp 95% evidence | 15.4/25 ROCE 29.8% · OPM 13% 95% evidence | 8.1/20 P/E 15.9× · PEG — 50% evidence | 6.9/20 RS sector -7% · RS bench -0.5% · 1Y 9%6 of 12 weeks ahead 100% evidence |
| Exact sum: 16.8 + 15.4 + 8.1 + 6.9 = 47.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 40Zensar Technologies LtdZENSARTECH | 46.6/100Mixed-negative evidence100% evidence | ASLEEP | 15.6/35 Revenue 8% · PAT 15.3% · OPM change 0 pp 100% evidence | 13.6/25 ROCE 22.8% · OPM 15% 100% evidence | 14.3/20 P/E 12.2× · PEG 1.11 100% evidence | 3.1/20 RS sector -33% · RS bench -28.6% · 1Y -45.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.6 + 13.6 + 14.3 + 3.1 = 46.6 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 41Unicommerce eSolutions LtdUNIECOM | 46.6/100Mixed-negative evidence74% evidence | ASLEEP | 14.4/35 Revenue 38.4% · PAT 18.1% · OPM change -8.1 pp 95% evidence | 16.5/25 ROCE 21.1% · OPM 10.6% 95% evidence | 9.1/20 P/E 44.1× · PEG — 15% evidence | 6.6/20 RS sector -14.5% · RS bench -19.2% · 1Y -44.1%0 of 10 weeks ahead 70% evidence |
| Exact sum: 14.4 + 16.5 + 9.1 + 6.6 = 46.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 42XT Global Infotech LtdXTGLOBAL | 46.5/100Mixed-negative evidence61% evidence | 18.4/35 Revenue 85.4% · PAT 29.4% · OPM change -6.6 pp 53% evidence | 9.4/25 ROCE 7.5% · OPM 9.5% 71% evidence | 9.1/20 P/E 40.8× · PEG — 50% evidence | 9.6/20 RS sector -1% · RS bench -12.7% · 1Y -21.9%2 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 18.4 + 9.4 + 9.1 + 9.6 = 46.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 43Wipro LtdWIPRO | 45.0/100Mixed-negative evidence100% evidence | BASING | 12.9/35 Revenue 6.4% · PAT -1.7% · OPM change 0 pp 100% evidence | 15.3/25 ROCE 17.8% · OPM 19% 100% evidence | 13.5/20 P/E 12.5× · PEG 1.4 100% evidence | 3.3/20 RS sector -25.8% · RS bench -20.8% · 1Y -31.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12.9 + 15.3 + 13.5 + 3.3 = 45 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 44Excelsoft Technologies LtdEXCELSOFT | 44.3/100Mixed-negative evidence60% evidence | TURNING | 12.0/35 Revenue 26.8% · PAT 4.2% · OPM change -1.8 pp 95% evidence | 12.2/25 ROCE 13.6% · OPM 16.3% 95% evidence | 10.1/20 P/E 18.7× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 10 weeks ahead 0% evidence |
| Exact sum: 12 + 12.2 + 10.1 + 10 = 44.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 45Sonata Software LtdSONATSOFTW | 43.1/100Mixed-negative evidence100% evidence | BREAKING OUT | 9.0/35 Revenue 4% · PAT 7.9% · OPM change 0 pp 100% evidence | 13.6/25 ROCE 30.7% · OPM 5% 100% evidence | 13.1/20 P/E 14.7× · PEG 0.81 100% evidence | 7.4/20 RS sector -17.3% · RS bench -12.1% · 1Y -25.9%11 of 12 weeks ahead 100% evidence |
| Exact sum: 9 + 13.6 + 13.1 + 7.4 = 43.1 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 4663 Moons Technologies Ltd63MOONS | 43.1/100Thin evidence · provisional58% evidence | BREAKING OUT | 20.6/35 Revenue 100% · PAT -80% · OPM change 128 pp 71% evidence | 3.4/25 ROCE -3.7% · OPM -52% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.1/20 RS sector -22.4% · RS bench 28.9% · 1Y -1.6%10 of 11 weeks ahead 70% evidence |
| Exact sum: 20.6 + 3.4 + 10 + 9.1 = 43.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 47Magellanic Cloud LtdMCLOUD | 38.9/100Mixed-negative evidence81% evidence | TURNING | 9.6/35 Revenue 13.7% · PAT 6.7% · OPM change -7 pp 95% evidence | 13.9/25 ROCE 19.8% · OPM 28% 95% evidence | 11.9/20 P/E 13.6× · PEG — 50% evidence | 3.5/20 RS sector -54.4% · RS bench -23.4% · 1Y -68%6 of 11 weeks ahead 70% evidence |
| Exact sum: 9.6 + 13.9 + 11.9 + 3.5 = 38.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 48Innovana Thinklabs LtdINNOVANA | 38.7/100Mixed-negative evidence81% evidence | TURNING | 8.7/35 Revenue 26% · PAT -39% · OPM change -32.5 pp 95% evidence | 11.3/25 ROCE 15.8% · OPM 17.6% 95% evidence | 9.0/20 P/E 21.9× · PEG — 50% evidence | 9.7/20 RS sector -0.4% · RS bench -15.1% · 1Y -40.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 8.7 + 11.3 + 9 + 9.7 = 38.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 49Kellton Tech Solutions LtdKELLTONTEC | 36.2/100Mixed-negative evidence87% evidence | BASING | 10.0/35 Revenue 9.5% · PAT 9.6% · OPM change -1 pp 95% evidence | 9.7/25 ROCE 15% · OPM 11% 95% evidence | 11.9/20 P/E 8× · PEG — 50% evidence | 4.6/20 RS sector -24.3% · RS bench -19.4% · 1Y -45.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 10 + 9.7 + 11.9 + 4.6 = 36.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 50Aurionpro Solutions LtdAURIONPRO | 36.1/100Mixed-negative evidence93% evidence | ASLEEP | 12.9/35 Revenue 14.8% · PAT 5.1% · OPM change -3 pp 100% evidence | 10.7/25 ROCE 16.3% · OPM 17% 100% evidence | 10.0/20 P/E 18× · PEG 1.39 65% evidence | 2.5/20 RS sector -30.2% · RS bench -25.6% · 1Y -47.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 12.9 + 10.7 + 10 + 2.5 = 36.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 51Allied Digital Services LtdADSL | 35.5/100Mixed-negative evidence74% evidence | BASING | 14.2/35 Revenue 19.1% · PAT 5.6% · OPM change 0 pp 95% evidence | 6.5/25 ROCE 7.4% · OPM 9% 95% evidence | 10.7/20 P/E 14.6× · PEG — 15% evidence | 4.1/20 RS sector -29.8% · RS bench -24.4% · 1Y -39.4%1 of 10 weeks ahead 70% evidence |
| Exact sum: 14.2 + 6.5 + 10.7 + 4.1 = 35.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 52Mindteck (India) LtdMINDTECK | 32.3/100Adverse evidence87% evidence | ASLEEP | 7.9/35 Revenue -1.8% · PAT 0.3% · OPM change -1.7 pp 95% evidence | 10.4/25 ROCE 15.1% · OPM 7.8% 95% evidence | 11.8/20 P/E 15.3× · PEG — 50% evidence | 2.2/20 RS sector -27.9% · RS bench -23.1% · 1Y -24.6%3 of 12 weeks ahead 100% evidence |
| Exact sum: 7.9 + 10.4 + 11.8 + 2.2 = 32.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 53Moschip Technologies LtdMOSCHIP | 31.1/100Adverse evidence87% evidence | TURNING | 7.7/35 Revenue 8.4% · PAT -33.6% · OPM change -3.9 pp 100% evidence | 7.0/25 ROCE 11% · OPM 8.2% 100% evidence | 3.7/20 P/E 129× · PEG 5.04 65% evidence | 12.7/20 RS sector 1.9% · RS bench 0.9% · 1Y -15.1%3 of 10 weeks ahead 70% evidence |
| Exact sum: 7.7 + 7 + 3.7 + 12.7 = 31.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 54Orient Technologies LtdORIENTTECH | 30.7/100Thin evidence · provisional54% evidence | BASING | 15.1/35 Revenue — · PAT — · OPM change -0.5 pp 19% evidence | 2.4/25 ROCE 8.4% · OPM 6.7% 95% evidence | 9.0/20 P/E 45.6× · PEG — 15% evidence | 4.2/20 RS sector -21.8% · RS bench -16.7% · 1Y -9.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.1 + 2.4 + 9 + 4.2 = 30.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 55Quick Heal Technologies LtdQUICKHEAL | 20.4/100Adverse evidence69% evidence | BASING | 6.2/35 Revenue -6.6% · PAT -80% · OPM change -22.1 pp 71% evidence | 1.8/25 ROCE -6% · OPM -39% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.4/20 RS sector -32.9% · RS bench -29.1% · 1Y -50.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 6.2 + 1.8 + 10 + 2.4 = 20.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 56Covance Softsol Ltd544361 | 66.8/100Thin evidence · provisional49% evidence | 25.8/35 Revenue 43.5% · PAT 100% · OPM change 19.7 pp 62% evidence | 17.8/25 ROCE 31.4% · OPM 23.1% 76% evidence | 11.1/20 P/E 12.9× · PEG — 15% evidence | 12.1/20 RS sector — · RS bench 48.4% · 1Y — 25% evidence | |
| Exact sum: 25.8 + 17.8 + 11.1 + 12.1 = 66.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 57Exato Technologies Ltdthis page544626 | 57.8/100Thin evidence · provisional38% evidence | TURNING | 21.0/35 Revenue — · PAT — · OPM change 3.4 pp 45% evidence | 17.5/25 ROCE 26.8% · OPM 18% 76% evidence | 9.3/20 P/E 40× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —4 of 4 weeks ahead 0% evidence |
| Exact sum: 21 + 17.5 + 9.3 + 10 = 57.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 58Unified Data- Tech Solutions LtdUNIFIED | 56.1/100Thin evidence · provisional36% evidence | 16.9/35 Revenue — · PAT — · OPM change 1 pp 26% evidence | 18.8/25 ROCE 45.2% · OPM 15% 76% evidence | 10.2/20 P/E 18.6× · PEG — 15% evidence | 10.2/20 RS sector — · RS bench -1.2% · 1Y 15.3%0 of 12 weeks ahead 25% evidence | |
| Exact sum: 16.9 + 18.8 + 10.2 + 10.2 = 56.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 59Kody Technolab LtdKODYTECH | 54.2/100Thin evidence · provisional48% evidence | BREAKING OUT | 15.2/35 Revenue — · PAT — · OPM change -5 pp 19% evidence | 14.4/25 ROCE 16.8% · OPM 29% 95% evidence | 8.7/20 P/E 125× · PEG — 15% evidence | 15.9/20 RS sector 10.3% · RS bench 61.9% · 1Y 107.4%10 of 10 weeks ahead 70% evidence |
| Exact sum: 15.2 + 14.4 + 8.7 + 15.9 = 54.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 60Metalic Technoforge LtdMETA | 53.0/100Thin evidence · provisional27% evidence | 16.2/35 Revenue — · PAT — · OPM change -2 pp 13% evidence | 17.1/25 ROCE 36.1% · OPM 8% 76% evidence | 9.7/20 P/E 25.3× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -12.7%0 of 12 weeks ahead 0% evidence | |
| Exact sum: 16.2 + 17.1 + 9.7 + 10 = 53 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 61Veefin Solutions LtdVEEFIN | 47.3/100Thin evidence · provisional50% evidence | 17.7/35 Revenue — · PAT — · OPM change -5.1 pp 19% evidence | 10.6/25 ROCE 9.8% · OPM 19.7% 76% evidence | 12.2/20 P/E 27.7× · PEG — 50% evidence | 6.8/20 RS sector -7.2% · RS bench -24.9% · 1Y -40%0 of 12 weeks ahead 70% evidence | |
| Exact sum: 17.7 + 10.6 + 12.2 + 6.8 = 47.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 62Trident Techlabs LtdTECHLABS | 45.8/100Thin evidence · provisional40% evidence | 16.0/35 Revenue — · PAT — · OPM change -2 pp 15% evidence | 16.2/25 ROCE 26.7% · OPM 27% 71% evidence | 10.5/20 P/E 14.9× · PEG — 15% evidence | 3.1/20 RS sector -50.2% · RS bench -56.5% · 1Y -72.5%0 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 16 + 16.2 + 10.5 + 3.1 = 45.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 63ERP Soft Systems Ltd530909 | 44.2/100Thin evidence · provisional41% evidence | 19.8/35 Revenue 19.1% · PAT 100% · OPM change -1.1 pp 53% evidence | 8.0/25 ROCE 1.6% · OPM 1.7% 57% evidence | 8.8/20 P/E 74.9× · PEG — 15% evidence | 7.6/20 RS sector — · RS bench -47.6% · 1Y -59.7%0 of 12 weeks ahead to 2026-03-29 25% evidence | |
| Exact sum: 19.8 + 8 + 8.8 + 7.6 = 44.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 64IDream Film Infrastructure Company Ltd504375 | 38.2/100Thin evidence · provisional35% evidence | TURNING | 12.8/35 Revenue — · PAT 100% · OPM change — 33% evidence | 3.1/25 ROCE -9.2% · OPM -25.8% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 12.3/20 RS sector — · RS bench 78% · 1Y —8 of 8 weeks ahead 25% evidence |
| Exact sum: 12.8 + 3.1 + 10 + 12.3 = 38.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Exato Technologies Ltd's share price today?
Exato Technologies Ltd trades at ₹754. The company is valued at ₹759 Cr. The stock sits at the very top of its 52-week range (₹354–₹754), +63.7% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 39 weeks in. — as of 11 September 2026.
What were Exato Technologies Ltd's latest quarterly results?
Exato Technologies Ltd reported revenue of ₹43.7 Cr and net profit of ₹5.6 Cr for the Jun 26 quarter. Revenue rose 50.2% and profit rose 104.3% year on year. Earnings per share were ₹5.60. The operating margin was 18.0%, 3.4 pp higher than a year earlier. — as of 11 September 2026.
What is Exato Technologies Ltd's revenue?
Exato Technologies Ltd reported revenue of ₹43.7 Cr in the Jun 26 quarter, +50.2% year on year. For the full FY26 fiscal year, revenue was ₹168 Cr (+35.5%). Over the last 3 years revenue compounded at 32.0% a year. — as of 11 September 2026.
What is Exato Technologies Ltd's profit?
Exato Technologies Ltd earned ₹5.6 Cr of net profit in the Jun 26 quarter, +104.3% year on year. Full-year FY26 profit was ₹16.0 Cr. The operating margin ran 18.0% in the latest quarter. — as of 11 September 2026.
What is Exato Technologies Ltd's market cap?
Exato Technologies Ltd's market capitalisation is ₹759 Cr at a share price of ₹754. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Exato Technologies Ltd's P/E ratio?
Exato Technologies Ltd trades at a P/E of 40.0×, at the most expensive it has been in 1 years, against a long-run median of 0.1×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Exato Technologies Ltd pay a dividend?
No — Exato Technologies Ltd has recorded a dividend payout of 0% of profit in each of its last 4 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 11 September 2026.
Is Exato Technologies Ltd overvalued?
On its own history, Exato Technologies Ltd looks expensive: its P/E of 40.0× sits at the most expensive it has been in 1 years (long-run median 0.1×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is Exato Technologies Ltd growing?
Yes — Exato Technologies Ltd is growing: latest-quarter revenue +50.2% year on year, profit +104.3%, and the margin +3.4 pp at 18.0%. The 3-year compound rates are 32.0% (revenue) and 47.4% (profit). The earnings engine currently reads: improving — as of 11 September 2026.
How is Exato Technologies Ltd performing?
Exato Technologies Ltd is in a confirmed uptrend, 39 weeks in. Its latest quarter's revenue rose 50.2% and profit rose 104.3% year on year. This describes what the data did, not a rating. — as of 11 September 2026.
Is Exato Technologies Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 39 of stage 2), trading +63.7% versus its 200-day average and at the very top of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Will Exato Technologies Ltd's share price go up?
This page publishes no price forecast for Exato Technologies Ltd. What it measures instead: the share price is ₹754, the price is in a confirmed uptrend 39 weeks in. Its P/E of 40.0× sits at the 100th percentile of its own 1-year range. — as of 11 September 2026.
Who owns Exato Technologies Ltd?
Promoters hold 54.7% of Exato Technologies Ltd, foreign institutions 0.0%, domestic institutions 7.9% and the public 37.4% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 11 September 2026.
Does Exato Technologies Ltd have too much debt?
No — Exato Technologies Ltd's debt-to-equity is 0.24, and operating profit covers the interest bill 12×. FY26 borrowings were ₹21.0 Cr against equity of ₹88.0 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is Exato Technologies Ltd's capex?
Exato Technologies Ltd spent ₹32.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹13.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Exato Technologies Ltd's cash flow?
Exato Technologies Ltd generated ₹2.0 Cr of operating cash flow in FY26 and ₹−11.0 Cr of free cash flow after ₹13.0 Cr of capital spending. Reported profit that year was ₹16.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Exato Technologies Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 3% of Exato Technologies Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹2.0 Cr against reported profit of ₹16.0 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 11 September 2026.
Where is Exato Technologies Ltd in its business cycle?
Exato Technologies Ltd's FY26 operating margin was 14.0%, against a 4-year band of 7.0%–14.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 18.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What could break the Exato Technologies Ltd story?
The sharpest disagreement: profits are rising, but only 3% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Exato Technologies Ltd a stock worth studying right now?
This is not investment advice. The machine read: Exato Technologies Ltd is strength at full price. The numbers are improving — and a P/E at the 100th percentile of its own range says the market knows. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!